Health Care·April 30, 2026
CytomX Therapeutics (NASDAQ: CTMX) to Report Q1 2026 Results on May 7
CytomX slipped 1.70% ahead of May 7 earnings announcement; biotech faces revenue collapse and mounting losses.
CytomX Therapeutics Inc. (NASDAQ: CTMX) Stock News & Analysis
CytomX Therapeutics Inc. (NASDAQ: CTMX) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight tracks CTMX across all major catalysts: quarterly earnings reports, analyst upgrades and downgrades, mergers and acquisitions, regulatory decisions, and significant price moves driven by sector or macro developments. This page centralises 2 articles published since April 30, 2026, providing investors with timely, data-driven analysis of CytomX Therapeutics Inc.'s financial performance and competitive position. New coverage is added each trading day.
CTMX Coverage -- 2 Articles
Earnings Report·May 7, 2026
CytomX Therapeutics (NASDAQ: CTMX) Crushes Q1 Sales Estimate Despite Earnings Miss
CytomX's Q1 revenue more than doubled consensus, though per-share loss exceeded guidance in preliminary results.
3 min readRead article
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.